You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A project to use the host response to classify acute respiratory infections has been spun off into a company called Host Response, and is seeking industry partners.
The startup plans to launch research-use diagnostic tests this year and support customers wishing to build custom assays.
The firm showed 98 percent sensitivity and 100 percent specificity across all major HCV genotypes in a recent study.
The assay could provide detection of HBV infection at early stages, potentially preventing progression to cirrhosis or hepatocellular carcinoma.
Using an immunoassay as an initial screening tool saved approximately $36,000 over multiplex PCR panel use alone when performed in a period of high flu prevalence.
The technology will measure cancer-associated miRNAs using optical amplification with quantum dots and photonic crystals.
The system will enable testing direct from a tube of blood using peptide nucleic acids-based methods to improve specificity.
The firm is also working on expanding its CTC capture capabilities beyond epithelial cells and will present multiple myeloma applications at an upcoming conference.
Although other groups have been developing noninvasive prenatal testing using digital PCR, BioCore claims to be the first to offer a test commercially.
The company is combining digital recruiting methods with at-home sample collection to speed up the study process.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.